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Research letter
Angiopoietin-like 3 and subclinical
peripheral arterial disease: Evidence from
the Brisighella Heart Study
Massimiliano Ruscica1, Chiara Macchi1, Federica Fogacci2,
Nicola Ferri3, Elisa Grandi2, Elisabetta Rizzoli2,
Sergio D’Addato2, Claudio Borghi2 and Arrigo FG Cicero2;
on behalf of the Brisighella Heart Study Group*
Angiopoietin-like 3 (ANGPTL3) is a 70kDa protein
primarily expressed in the liver. The main physiological
role is related to the inhibition of lipoprotein and
endothelial lipases, thus affecting triglyceride hydroly-
sis.1 The role of ANGPTL3 in atherosclerosis has
emerged from genetics: carriers of loss of function
(LOF) mutations of ANGPTL3, leading to low plasma
levels, had a reduced risk of coronary artery disease and
a lipid profile characterised by dramatic reductions of
low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol and triglycerides.2
However, although homozygous or compound hetero-
zygous for ANGPTL3 LOF had a reduced capacity to
promote cell cholesterol efflux, no clinical evidence of
accelerated atherosclerosis was found.3 ANGPTL3 also
influences the endothelial cell adhesion and stimulates
the proliferation of haematopoietic stem cells,4 both
potentially atherosclerosis associated.
As, to date, in a general population no data have
been reported on a possible direct involvement of
ANGPTL3 with arterial disease, the present retrospec-
tive study was aimed to evaluate the relationship
between ANGPTL3 plasma levels and extra-coronary
arterial health, as assessed by the ankle–brachial blood
pressure index (ABI), a validated, non-invasive tool for
peripheral artery disease (PAD) screening.5 Moreover,
levels of proprotein convertase subtilisn/kexin type 9
(PCSK9), which may play a crucial role in vascular
aging, were also evaluated.6
The Brisighella Heart Study is a longitudinal popu-
lation study on a randomly allocated sample represen-
tative of the entire population of Brisighella, a rural
northern Italian village. The study, carried out in agree-
ment with the Declaration of Helsinki, was approved
by the institutional ethics board of the University
Hospital of Bologna.7
Plasma ANGPTL3 and PCSK9 were determined
by commercial enzyme-linked immunosorbent assay
(ELISA) kits.8 Blood pressure was measured according
to the guidelines of the European Society of Cardiology
and of the European Society of Hypertension. ABI, aug-
mentation index (AI) and carotid-femoral pulse wave
velocity (cfPWV) were measured by a Vicorder appara-
tus (Skidmore Medical Ltd., UK).9 Patients with no his-
tory of clinical PAD but with a low ABI (0.90) were
considered as presenting with subclinical PAD.
A bivariate correlation between age, blood pressure,
heart rate, LDL-cholesterol, HDL-cholesterol, trigly-
cerides, lipoprotein (a) (Lp(a)), serum uric acid
(SUA), estimated glomerular filtration rate (eGFR),
cfPWV and ABI was investigated. In a logistic regres-
sion analysis, ABI was considered as a dependent vari-
able, whereas gender, physical activity, cfPWV, Lp(a),
PCSK9, ANGPTL3, SUA and eGFR were considered
as independent variables. Data were age and LDL-cho-
lesterol adjusted.
Among 2939 subjects, after a screening on PAD
based on the ABI measurement, 1968 subjects who par-
ticipated in the 2016 survey were selected. These com-
prise a sample of 241 post-menopausal women (52.5%)
and 218 age-matched men (47.5%) with normal (<1.10
ABI <1.40) or abnormal (0.90 or 1.40) ABI values.
Treatment with statins or vasodilating agents was
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considered as exclusion criteria as was the case for
borderline ABI values (between 0.91 and 1.10).10
Menopausal age was based on patient self-reporting
of menstrual cessation.
As reported in Table 1, subjects with optimal
(n¼ 378) or abnormal (n¼ 81) ABI values were age-
matched (67.6 vs. 68.1 years), with no differences in
haemodynamic characteristics, i.e. blood pressure,
AI and cfPVW. Thirty-six per cent of subjects were
hypertensive and 33% were overweight. When the
lipid profile was evaluated, no statistically significant
differences were found between the two groups.
No-one had a diagnosis of diabetes. Conversely, differ-
ences between groups were found for baseline eGFR,
significantly lower in subjects with a more compro-
mised ABI, i.e. 59.4 8.9 versus 66.6 9.0 (P< 0.001)
and for PCSK9 levels, significantly lower in less com-
promised subjects, i.e. 336.1 69.3 ng/mL versus
354.2 67.9 ng/mL (P¼ 0.036). In the entire cohort,
PCSK9 levels were normally distributed, with a mean
value of 342.4 69.1 ng/mL. ANGPTL3 was not
normally distributed (133.2 50.8 ng/mL) and conse-
quently was log-transformed before further analyses.
Multivariate analyses adjusted for age and
LDL-cholesterol and carried out on the whole popula-
tion showed that ABI was mainly predicted by log
ANGPTL3 (odds ratio (OR) 1.110, 95% confidence
interval (CI) 1.008–1.192, P< 0.001), PCSK9 (OR
1.127, 95% CI 1.063–1.221, P¼ 0.001) and SUA (OR
1.203, 95% CI 1.104–1.311, P< 0.001). This last, along
with chronic kidney failure, are considered as emerging
risk factors for PAD. Gender, physical activity, Lp(a),
eGFR and cfPWV were not associated with ABI.
The significant predictors of ABI in the different
subgroups are reported in Table 2. In both men and
women, the parameter best associated with ABI was
SUA; only in men ABI was further predicted by
ANGPTL3 (b¼ 1.099, 95% CI 1.042–1.219) and
PCSK9 (b¼ 1.129, 95% CI 1.007–1.268) levels. When
subjects were classified based on normal or abnormal
ABI values, ANGPTL3 was an ABI predictor in both
groups (b¼ 1.103, 95% CI 1.018–1.134 and b¼ 1.184,
95% CI 1.018–1.223, respectively), whereas SUA and
PCSK9 levels were predictive parameters only in the
abnormal ABI group. When subjects were classified
as having normal or impaired renal function,
ANGPTL3 and PCSK9 remained significant ABI pre-
dictors in both groups, whereas SUA was predictive
only in subjects with preserved renal function.
In the general Caucasian population PAD is the
third leading cause of atherosclerotic cardiovascular
morbidity, after coronary artery disease and stroke,
Table 1. Main characteristics of the selected subjects.
Parameters
Normal ABI (n¼ 378) Abnormal ABI (n¼ 81)
P valueMean SD Mean SD
Age (years) 67.6 4.6 68.1 5.1 0.095
BMI (kg/m2) 27.1 3.8 27.1 4.1 0.978
SBP (mmHg) 136.6 12.8 139.5 19.6 0.566
DBP (mmHg) 75.2 8.4 73.3 7.7 0.086
AI 28.2 7.3 29.4 8.1 0.242
cfPWV (m/s) 9.5 2.3 9.9 2.7 0.290
ABI 1.1 0.1 0.8 0.1 <0.001
Total cholesterol (mg/dL) 227.1 29.1 216.9 32.9 0.054
LDL-cholesterol (mg/dL) 149.7 26.6 141.3 31.9 0.074
HDL-cholesterol (mg/dL) 51.6 5.2 51.0 6.1 0.756
Triglycerides (mg/dL) 129.9 49.5 122.4 41.8 0.376
Lipoprotein (a) (mg/dL) 24.8 11.5 22.0 9.1 0.469
PCSK9 (ng/mL) 336.1 69.3 354.2 67.9 0.036
Angiopoietin-like 3 (ng/mL) 132.9 52.5 134.5 41.9 0.806
Fasting plasma glucose (mg/dL) 96.0 7.4 97.1 8.3 0.592
Serum uric acid (mg/dL) 5.3 1.2 5.2 1.2 0.357
eGFR (ml/min) 66.6 9.0 59.4 8.9 <0.001
ABI: ankle brachial index; AI: augumentation index; BMI: body mass index; cfPWV: carotid–femoral pulse wave velocity; DBP:
diastolic blood pressure; eGFR: estimated glomerular filtration rate; HDL: high-density lipoprotein; LDL: low-density lipoprotein;
PCSK9: proprotein convertase subtilisin/kexin type 9; SBP: systolic blood pressure; SD: standard deviation.
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with a prevalence of approximately 3.5%. In order to
prevent the frequently rapid disease progression, early
identification of PAD and its risk factors are strongly
suggested.11,12 ABI measurement is considered as most
appropriate for PAD screening in the general popula-
tion. Low ABI (<0.9) values are associated with a sig-
nificant risk of all-cause (risk ratio (RR) 2.52, 95% CI
2.26–2.82) and cardiovascular mortality (RR: 2.94,
95% CI 2.72–3.18) as well as of cerebrovascular
events (RR 2.17, 95% CI 1.90–2.47).13 In the described
cohort, ANGPTL3 was found to be significantly asso-
ciated with suboptimal ABI in overall healthy elderly
people.
In healthy volunteers, ANGPTL3 was positively
associated with femoral artery intima media thickness
independent of age, sex, smoking, body mass index,
lipids, systolic blood pressure and the insulin resistance
index.14 Thus, in humans, ANGPTL3 may be closely
associated with arterial wall thickness both in the car-
otid and femoral beds.
While ANGPTL3 was associated with ABI in sub-
jects with both normal and abnormal ABI, when
PCSK9 was considered the association was present
only in the subgroup with abnormal ABI. In the same
population, we have previously demonstrated that
PCSK9 was directly correlated to arterial stiffness, as
assessed by cfPWV.15 It is thus reasonable to conclude
that ANGPTL3 could be an early predictor of PAD,
whereas elevated PCSK9 may be a reliable biomarker
of the disease severity.
The possible mechanism of the association between
ANGPTL3 and abnormal ABI may be ascribed to a
direct vascular wall damage exerted by ANGPTL3,
independent of triglyceride metabolism, and explained
by the following evidence: (a) the C-terminal fibrino-
gen-like domain of ANGPTL3 can bind to the integrin
aVb3 expressed on endothelial cells; (b) the binding of
ANGPTL3 to integrin aVb3 may facilitate the develop-
ment of atherosclerotic plaques by promoting intrapla-
que angiogenesis; (c) integrin aVb3 is involved in foam
cell formation and inflammation.16 In conclusion, in a
large group of healthy mature subjects, ABI was sig-
nificantly associated with ANGPTL3 levels, particu-
larly in women.
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